NGNE

SEC source: 0001209191-20-027683 · doc4.xml · derivative · entry 1

Noonberg Sarah B. · CIK 0001706301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-05-05

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-027694 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-05-05

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-027689 · doc4.xml · derivative · entry 1

SIMPSON TODD E · CIK 0001216477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-05-05

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-027679 · doc4.xml · derivative · entry 1

Nolan Sean P. · CIK 0001569926 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-05-05

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning June 5, 2020 until the option is fully vested on May 5, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 13

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,041,211

F9 · kind: The Reporting Persons? pecuniary interest in the sales of an aggregate of 19,668 shares of the Issuer?s common stock on April 1, 2020 and April 2, 2020 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of the Reporting Persons? pecuniary interest in 9,100 shares of the Issuer?s common stock purchased at prices ranging from $8.86 to $9.11 per share on March 26, 2020 and 10,568 shares of the Issuer?s common stock purchased at prices ranging from $8.88 to $9.115 per share on March 28, 2020. The Reporting Persons have agreed to pay to the Issuer the full amount of the Reporting Persons? pecuniary interest in the deemed profit realized in connection with the short-swing transactions, less transaction costs.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 12

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,041,311

F9 · kind: The Reporting Persons? pecuniary interest in the sales of an aggregate of 19,668 shares of the Issuer?s common stock on April 1, 2020 and April 2, 2020 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of the Reporting Persons? pecuniary interest in 9,100 shares of the Issuer?s common stock purchased at prices ranging from $8.86 to $9.11 per share on March 26, 2020 and 10,568 shares of the Issuer?s common stock purchased at prices ranging from $8.88 to $9.115 per share on March 28, 2020. The Reporting Persons have agreed to pay to the Issuer the full amount of the Reporting Persons? pecuniary interest in the deemed profit realized in connection with the short-swing transactions, less transaction costs.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.795 to $11.7425, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 11

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,051,045

F13 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.805 to $11.91, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 10

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,050,045

F12 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.795 to $11.78, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 9

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,011,745

F9 · kind: The Reporting Persons? pecuniary interest in the sales of an aggregate of 19,668 shares of the Issuer?s common stock on April 1, 2020 and April 2, 2020 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of the Reporting Persons? pecuniary interest in 9,100 shares of the Issuer?s common stock purchased at prices ranging from $8.86 to $9.11 per share on March 26, 2020 and 10,568 shares of the Issuer?s common stock purchased at prices ranging from $8.88 to $9.115 per share on March 28, 2020. The Reporting Persons have agreed to pay to the Issuer the full amount of the Reporting Persons? pecuniary interest in the deemed profit realized in connection with the short-swing transactions, less transaction costs.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.85 to $11.88, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 8

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,011,945

F9 · kind: The Reporting Persons? pecuniary interest in the sales of an aggregate of 19,668 shares of the Issuer?s common stock on April 1, 2020 and April 2, 2020 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of the Reporting Persons? pecuniary interest in 9,100 shares of the Issuer?s common stock purchased at prices ranging from $8.86 to $9.11 per share on March 26, 2020 and 10,568 shares of the Issuer?s common stock purchased at prices ranging from $8.88 to $9.115 per share on March 28, 2020. The Reporting Persons have agreed to pay to the Issuer the full amount of the Reporting Persons? pecuniary interest in the deemed profit realized in connection with the short-swing transactions, less transaction costs.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.76 to $11.72, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 7

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,021,579

F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.42 to $11.91, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 6

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,012,579

F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.41 to $11.41, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 5

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,979,079

F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.65 to $10.84, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 4

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,971,579

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.64 to $10.64, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 3

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,949,079

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.14 to $10.88, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 2

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,946,379

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.12 to $10.11, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001104659-20-043863 · tm2014824d2_4.xml · nonDerivative · entry 1

Redmile Group, LLC · CIK 0001425738 · 10% owner

Green Jeremy · CIK 0001650527 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,916,579

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.48, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.

F2 · ownership.nature: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC (?Redmile?) and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-20-019430 · doc4.xml · derivative · entry 2

Ho Robert · CIK 0001806254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-03-16

F4 · derivative.exercise_date: The option vests as to 1/4 of the total shares on March 16, 2021, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-019430 · doc4.xml · derivative · entry 1

Ho Robert · CIK 0001806254 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

SEC source: 0001638599-19-001057 · doc4_6406.xml · derivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,765,333

Underlying: Common Stock · 1,160,148 shares

Expires not disclosed

F6 · derivative.exercise_price: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.exercise_price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · price: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · derivative.exercise_date: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.exercise_date: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · derivative.expiration_date: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.expiration_date: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · derivative.underlying_shares: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.underlying_shares: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · ownership.nature: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · ownership.nature: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F9 · ownership.nature: As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Pre-funded Warrants reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-001057 · doc4_6406.xml · derivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,161,048

Underlying: Common Stock · 1,160,148 shares

Expires not disclosed

F6 · derivative.exercise_price: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.exercise_price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · price: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · derivative.exercise_date: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.exercise_date: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · derivative.expiration_date: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.expiration_date: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · derivative.underlying_shares: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · derivative.underlying_shares: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F6 · ownership.nature: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · ownership.nature: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F8 · ownership.nature: As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Pre-funded Warrants reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-001057 · doc4_6406.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,107,331

F6 · price: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock of the Issuer reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · ownership.nature: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-001057 · doc4_6406.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 290,409

F6 · price: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · price: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F4 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F6 · ownership.nature: 667 and Life Sciences entered into an exchange agreement on December 17, 2019 with the Issuer (the "Exchange Agreement") pursuant to which on a 1 for 1 basis they exchanged 1,160,148 and 9,765,333 shares of Common Stock, respectively, for non-voting pre-funded warrants ("Pre-funded warrants") with an exercise price of $0.000001 per share. The Pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of Common Stock (the "Beneficial Ownership Limitation").

F7 · ownership.nature: By written notice to the Issuer, the Funds may from time to time increase or decrease the Beneficial Ownership Limitation applicable to that Fund to any other percentage not in excess of 19.99%. Any such change will not be effective until the 61st day after such notice is delivered to the Issuer. The Issuer's board of directors (the "Board") and the pricing committee of the Board approved the transactions pursuant to the Exchange Agreement in advance of the consummation of such transactions.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-001057 · doc4_6406.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 12,872,664

F3 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 250,037 and 2,767,505 shares of Common Stock, respectively, for $8.40 per share in an underwritten public offering (the "Offering") that closed on December 20, 2019.

F5 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock of the Issuer reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-001057 · doc4_6406.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,450,557

F3 · ownership.nature: 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") purchased 250,037 and 2,767,505 shares of Common Stock, respectively, for $8.40 per share in an underwritten public offering (the "Offering") that closed on December 20, 2019.

F4 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0000899243-19-029824 · doc4.xml · nonDerivative · entry 3

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,198,686

F2 · shares: Represents shares purchased in an underwritten public offering of the Issuer's Common Stock.

SEC source: 0000899243-19-029824 · doc4.xml · nonDerivative · entry 2

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,079,639

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock converted into 100 shares of the Issuer's Common Stock upon the approval of the Issuer's stockholders on November 12, 2019.

SEC source: 0000899243-19-029824 · doc4.xml · nonDerivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Convertible Preferred Stock converted into 100 shares of the Issuer's Common Stock upon the approval of the Issuer's stockholders on November 12, 2019.

SEC source: 0001638599-19-000919 · doc4_6329.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-10-09

F1 · derivative.exercise_date: 22,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of Neoleukin Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2014 Equity Incentive Plan to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in her capacity as a director of the Issuer. The Stock Options with a strike price of $2.82 vest in 3 equal annual installments beginning on October 10, 2020 and expire on October 9, 2029. M. Cantey Boyd serves on the board of directors of the Issuer (the "Board") as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F1 · ownership.nature: 22,000 non-qualified stock options ("Stock Options") exercisable solely into common stock of Neoleukin Therapeutics, Inc. (the "Issuer") were granted under the Issuer's 2014 Equity Incentive Plan to M. Cantey Boyd, a full-time employee of Baker Bros. Advisors LP (the "Adviser") in her capacity as a director of the Issuer. The Stock Options with a strike price of $2.82 vest in 3 equal annual installments beginning on October 10, 2020 and expire on October 9, 2029. M. Cantey Boyd serves on the board of directors of the Issuer (the "Board") as a representative of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds").

F2 · ownership.nature: The policies of the Funds and the Adviser does not permit full-time employees of the Adviser or managing members of the Adviser GP (as defined below) to receive compensation for serving as a director of the Issuer. The Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the Stock Options. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options (i.e. no direct pecuniary interest).

F3 · ownership.nature: The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. The Adviser has investment and dispositive power over the Stock Options and any common stock of the Issuer received as a result of the exercise of stock options.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0000899243-19-025573 · doc4.xml · derivative · entry 1

Noonberg Sarah B. · CIK 0001706301 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-10-09

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000899243-19-025572 · doc4.xml · derivative · entry 1

Nolan Sean P. · CIK 0001569926 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-10-09

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000899243-19-025575 · doc4.xml · derivative · entry 1

SIMPSON TODD E · CIK 0001216477 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-10-09

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date

SEC source: 0000899243-19-025571 · doc4.xml · derivative · entry 1

Williams Lewis T · CIK 0001475714 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2029-10-09

F1 · derivative.exercise_date: The options will vest as to 1/3 of the total number of shares underlying the options on each of October 10, 2020, October 10, 2021 and October 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0000899243-19-023329 · doc4.xml · nonDerivative · entry 3

DRACHMAN JONATHAN G · CIK 0001588467 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 584,428

F3 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $3.06 and the highest price at which shares were purchased was $3.50.

SEC source: 0000899243-19-023329 · doc4.xml · nonDerivative · entry 2

DRACHMAN JONATHAN G · CIK 0001588467 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 447,992

F2 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $3.00 and the highest price at which shares were purchased was $3.10.

SEC source: 0000899243-19-023329 · doc4.xml · nonDerivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 411,250

F1 · price: Represents the weighted average purchase price. The lowest price at which shares were purchased was $2.82 and the highest price at which shares were purchased was $2.85. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

SEC source: 0000899243-19-022733 · doc4.xml · derivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,650,000

Underlying: Common Stock · 1,650,000 shares

Expires 2029-08-31

F1 · derivative.exercise_date: The options will vest as to 25% of the total shares on August 31, 2020, and then 2.0833% of the total shares will vest monthly thereafter, such that the option is fully vested on August 31, 2023, subject to the Reporting Person's provision of service to the issuer on each vesting date.

SEC source: 0001213900-19-015390 · ownership.xml · nonDerivative · entry 2

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,428

F2 · security: Each share of Series A Convertible Preferred Stock will become convertible into 100 shares of the Issuer's Common Stock, subject to and contingent upon the approval of the Issuer's stockholders in accordance with the Nasdaq Stock Market Rules. Under the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated August 5, 2019, among Neoleukin, Aquinox Pharmaceuticals, Inc. (the "Issuer") and Apollo Sub, Inc., the Issuer has agreed to use commercially reasonable efforts to call and hold a meeting of the Issuer's stockholders to obtain the requisite approval for the conversion of the Series A Convertible Preferred Stock into shares of Common Stock, for purposes of the Nasdaq Stock Market Rules, as soon as practicable and in any event no later than 100 days after the date of the Merger Agreement.

F1 · price: In connection with the merger of Neoleukin Therapeutics, Inc. ("Neoleukin") into Apollo Sub, Inc. (the "Merger"), 950,000 shares of Common Stock of Neoleukin held by the Reporting Person were exchanged for 334,428 shares of Common Stock and 7,428 shares of Series A Convertible Preferred Stock.

SEC source: 0001213900-19-015390 · ownership.xml · nonDerivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 334,428

F1 · price: In connection with the merger of Neoleukin Therapeutics, Inc. ("Neoleukin") into Apollo Sub, Inc. (the "Merger"), 950,000 shares of Common Stock of Neoleukin held by the Reporting Person were exchanged for 334,428 shares of Common Stock and 7,428 shares of Series A Convertible Preferred Stock.

SEC source: 0000899243-19-023581 · doc4a.xml · nonDerivative · entry 2

DRACHMAN JONATHAN G · CIK 0001588467 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,616

F1 · security: This amended Form 4 reflects a correction to the number of shares of Common Stock and Series A Preferred Stock issued to the Reporting Person in connection with the merger of Neoleukin Therapeutics, Inc. ("Neoleukin") into Apollo Sub, Inc. (the "Merger"), as reported on Form 4 filed on August 12, 2019, and in the Reporting Person's total direct holdings as reported on Form 4 filed on September 11, 2019.

F3 · security: Each share of Series A Convertible Preferred Stock will become convertible into 100 shares of the Issuer's Common Stock, subject to and contingent upon the approval of the Issuer's stockholders in accordance with the Nasdaq Stock Market Rules. Under the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated August 5, 2019, among Neoleukin, Aquinox Pharmaceuticals, Inc. (the "Issuer") and Apollo Sub, Inc., the Issuer has agreed to use commercially reasonable efforts to call and hold a meeting of the Issuer's stockholders to obtain the requisite approval for the conversion of the Series A Convertible Preferred Stock into shares of Common Stock, for purposes of the Nasdaq Stock Market Rules, as soon as practicable and in any event no later than 100 days after the date of the Merger Agreement

F2 · price: In connection with the Merger, 1,613,614 shares of Common Stock of Neoleukin held by the Reporting Person, including 663,614 shares of Common Stock of Neoleukin issued upon conversion of convertible notes held by the Reporting Person immediately prior to the Merger, were exchanged for 568,039 shares of Common Stock and 12,616 shares of Series A Convertible Preferred Stock.

SEC source: 0000899243-19-023581 · doc4a.xml · nonDerivative · entry 1

DRACHMAN JONATHAN G · CIK 0001588467 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 568,039

F1 · security: This amended Form 4 reflects a correction to the number of shares of Common Stock and Series A Preferred Stock issued to the Reporting Person in connection with the merger of Neoleukin Therapeutics, Inc. ("Neoleukin") into Apollo Sub, Inc. (the "Merger"), as reported on Form 4 filed on August 12, 2019, and in the Reporting Person's total direct holdings as reported on Form 4 filed on September 11, 2019.

F2 · price: In connection with the Merger, 1,613,614 shares of Common Stock of Neoleukin held by the Reporting Person, including 663,614 shares of Common Stock of Neoleukin issued upon conversion of convertible notes held by the Reporting Person immediately prior to the Merger, were exchanged for 568,039 shares of Common Stock and 12,616 shares of Series A Convertible Preferred Stock.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 12

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,105,159

F9 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $3.03 to $3.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 11

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,200,520

F9 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $3.03 to $3.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 10

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,054,723

F8 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $2.94 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 9

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,195,956

F8 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $2.94 to $3.26, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 8

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 9,845,341

F7 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $2.955 to $2.960, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 7

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,177,013

F7 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $2.955 to $2.960, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 9,839,472

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $2.79 to $2.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,176,482

F6 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $2.79 to $2.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP),LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001638599-19-000703 · doc4_6190.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 9,773,904

F3 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $2.76 to $2.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

F5 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F10 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F11 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.